CD274 and neoplasm: To validate the ex vivo effect of MAP, we analyzed PD‐L1 ubiquitination levels in MC38 subcutaneous tumors post‐treatment and found a significant increase in ubiquitination, accompanied by a marked reduction in PD‐L1 expression in tumor tissues of the MAP‐treated group (Figure S7B, Supporting Information).